CKPT - Checkpoint Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.13
-0.08 (-1.90%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close4.21
Open4.26
Bid3.00 x 300
Ask4.75 x 100
Day's Range4.12 - 4.26
52 Week Range3.20 - 15.00
Volume16,974
Avg. Volume50,388
Market Cap105.348M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Checkpoint Therapeutics to Present at BIO CEO & Investor Conference

    NEW YORK, Feb. 06, 2018-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that James F. Oliviero, President and Chief Executive Officer, will present a company overview at the ...

  • GlobeNewswirelast month

    Checkpoint Therapeutics to Present at Biotech Showcase™ 2018

    NEW YORK, Jan. 03, 2018-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that President and Chief Executive Officer James F. Oliviero will present a company overview at Biotech ...

  • GlobeNewswire2 months ago

    Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018

    NEW YORK, Dec. 14, 2017-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that its senior management team will host institutional investor and partnering meetings at the LifeSci ...

  • Benzinga2 months ago

    Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together'

    Checkpoint Therapeutics Inc (NASDAQ: CKPT ), a nano-cap therapeutics company that focuses on developing anti-cancer agents , has lost more than half of its value over the past few months but some analysts ...

  • Zacks Small Cap Research2 months ago

    CKPT: A Smokin’ Opportunity in PD-L1 Therapy and Beyond

    NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) boasts an impressive portfolio of immuno-oncology and anti-cancer agents that have the potential for approvals as both mono- and combination therapies.  ...

  • Zacks Small Cap Research4 months ago

    Checkpoint Therapeutics (CKPT) Starts CK-301 Trials

    NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) announces the dosing of its first patient in a Phase I trial for CK-301, which we discuss in a prior article .  CK-301 is a fully human monoclonal IgG1 ...

  • Zacks Small Cap Research5 months ago

    Checkpoint Inhibitors Are Hot, and CKPT Has Something in the Oven

    NASDAQ:CKPT Checkpoint Therapeutics Inc. (NASDAQ:CKPT) holds a portfolio of targeted anti-cancer and immuno-oncology agents which it is developing for both mono- and combination therapies in solid tumors. ...

  • Zacks Small Cap Research7 months ago

    Checkpoint (CKPT): An Innovator of Immune-Enhanced Combination Therapies in Solid Tumors

    Checkpoint Therapeutics, Inc. (CKPT) is a majority-controlled subsidiary of Fortress Biotech (FBIO) focused on developing a portfolio of immune-enhanced combination cancer therapies in solid tumors.  Checkpoint’s strategy is to acquire, develop and commercialize immuno-oncology and targeted anti-cancer medicines by acquiring rights or ownership in promising molecules, then funding their research and development to bring the technologies to market.  The company’s portfolio currently consists of six drug candidates in preclinical and Phase I clinical trials.  Two of the compounds are immuno-oncology agents and four are targeted anti-cancer agents. Checkpoint plans to develop its drug candidates both as monotherapies, and then in combination with each other.  Importantly, owning all components of a combination therapy should provide Checkpoint with pricing leverage versus competitors upon commercialization.